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Objective: To study the role of hepatitis B virus with A1762T/G1764A double mutation in
liver  cirrhosis and hepatocellular carcinoma, and create a sensitive, fast, accurate assay for
detection of A1762T/G1764A double mutation.
Methods: We  developed an accurate and fast real-time ampliﬁcation refractory mutation sys-
tem to detect A1762T/G1764A double mutation. Cloned hepatitis B virus genome was used
as  a control. Assay sensitivity was determined by serial dilution and mixed template exper-
iments.  Speciﬁcity was determined by cross experiments with wild and mutant hepatitis B
virus. Fifty clinical samples were tested by the real-time ampliﬁcation refractory mutation
system  and the results were compared with sequencing.
Results: The real-time ampliﬁcation refractory mutation system had a sensitivity of 100
copies  of virus with these mutations, and 0.1% weak population virus with double mutation
could  be found in mixtures. A total of 50 randomly collected clinical samples were  detected
by  real-time ampliﬁcation refractory mutation system, and the results were consistent with
those by DNA sequencing. Hepatitis B virus genotype C was more  prevalent in 39 of 50 sam-
ples  than genotype B (11 samples), and about 75% of genotype C carried a double mutation
compared  to 45% of genotype B. However, the percentage of A1762T/G1764A double muta-
tion  in hepatitis B e antigen-negative (58.3%) samples was almost the same as in hepatitisB  e antigen-positive (61%) samples.
Conclusion: The real-time ampliﬁcation refractory mutation system is sensitive and speciﬁc
for  detection of hepatitis B virus double mutation.
over  the entire HBV genomic sequence. In China, the most
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDntroductionhronic infection with hepatitis B virus (HBV) is one of the
ajor  serious risk factors for liver cirrhosis and hepatocellu-
ar  carcinoma (HCC). HBV infection is associated with up to
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Este é um artigo Open Access sob a licença80–90% of HCC patients in the Asia–Paciﬁc region.1 Eight HBV
genotypes (A–H) have been identiﬁed based on the divergence
2,3prevalent  genotypes of HBV are B and C. Most of the HBV infec-
tion  cases in China are chronic.3–5 In addition, HBV genotype
C  can carry a higher risk for liver cirrhosis and HCC.6–9
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Table 1 – Primers and probes for detecting
A1762/G1764A double mutation.
Primer 5′–3′
Primer for full-length HBV clone
p1  CCGGAAAGCTTGAGCTCTTCTTTTTCACCTCTGCCTAATCA
p2  CCGGAAAGCTTGAGCTCTTCAAAAAGTTGCATGGTGCTGG
Primer for A1762T/G1764A sequencing
p3  GGACTCTTGGACTCTCAGC
p4  ATTTATGCCTACAGCCTCCTA
Primer and probe for RT-ARMS
p5  acCCGACCTTGAGGMRTACTT
p6  ACAGCCTCCTAGTACAAAGATgA262  b r a z j i n f e c t d 
Among the many  factors that may  contribute to patho-
genesis and carcinogenesis,10 scientists have found that HBV
A1762T/G1764A double mutation is a predictive biomarker
for  HCC development.8,9,11,12 This mutation is involved in the
mechanism of infection with hepatitis B e antigen (HBeAg)-
negative virus.13,14 A1762T/G1764A double mutation is more
prevalent in HBV genotype C, and correlates with increased
replication capacity.6 Furthermore, HBV genotype C with
1762T/1764A mutations is associated with a higher risk of
HCC,  and this association is independent of serum HBV
DNA  level.6,15 A recent study has indicated that quantiﬁ-
cation of the A1762T/G1764A mutant virus helps predicting
the  risk of HCC.16–18 Currently, A1762T/G1764A mutation is
routinely  detected by nucleotide sequencing of PCR prod-
ucts.  This method can only detect the mutant viruses when
it  comprises at least 25% of the total virus population.19
Although a sensitive, fast, and accurate assay for detecting
A1762T/G1764A double mutation has been reported, it was  a
laboratory-speciﬁc assay and could not be widely used in other
laboratories.19
In this study, we report an ampliﬁcation refractory muta-
tion  system (ARMS) PCR for detecting A1762T/G1764A double
mutation.
Materials  and  methods
Patient  samples  and  DNA  puriﬁcation
A total of 50 patient serum samples were  randomly retrieved
from  the Third People’s Hospital of Changzhou. HBV viral DNA
was  isolated from 200 L patient serum samples using the
QIAamp  DNA blood mini kit (Qiagen) and eluted into 50 L
buffer  according to manufacturer’s instructions.
Plasmid  standards  and  other  reagents
Full-length HBV genome was  cloned according to the method
of  Parekh et al.18,20 Brieﬂy, clinical samples with chronic HBV
infection  were  used. HBV DNA isolated by commercial kits was
ampliﬁed  by PCR in 50 L buffer containing 5 L 10× LAmp
buffer, 20 M dNTP, 0.3 M each primer (p1 and p2), 2.5 mM
Mg2+ and 5 U LAmp DNA Polymerase (Beijing Cowin Bioscience
Co.  Ltd., Beijing, China). PCR was  performed using a BioRad
Mycyle  PCR (Bio-Rad, Hercules, CA, USA) under the following
conditions: 94 ◦C for 2 min, followed by 94 ◦C for 30 s, 60 ◦C for
1  min, and 72 ◦C for 3 min  for 35 cycles, with a ﬁnal extension
of  5 min. The PCR products were  puriﬁed (Axygen Scientiﬁc,
Shanghai, China) and cloned into the pGEM-T Easy Vector Sys-
tem (Promega, Madison, WI,  USA). The plasmid was  identiﬁed
by  sequencing. The clones that carried the A1762T/G1764A
double mutation, A1762T and G1764A single mutations, and
wild  template were  used as the assay standards and quantiﬁed
by  using NanoDrop 2000 (Thermo Fisher Scientiﬁc, Waltham,
MA,  USA).Direct  PCR  sequencing
For identiﬁcation of the double mutation in the basal core pro-
moter  (BCP) region, HBV DNA was  ampliﬁed and sequencingp7  TACAGCCTCCTAGTACAAAGATCA
p8  Fam-TGGGAGGAGTTGGGGGAGGA-TAMRA
using the p3 and p4 primers and LAmp DNA Polymerase. The
thermal  program was  95 ◦C for 30 s, 55 ◦C for 30 s, and 72 ◦C for
30  s, for a total of 40 cycles. The PCR products were  separated
by  electrophoresis, puriﬁed using a Qiagen gel extraction kit,
and  sequencing was done with the BigDye terminator cycle-
sequencing reaction kit and Prism 3730 DNA analyzer (Life
Technology, Shanghai, China).
Real-time  ampliﬁcation  refractory  mutation  system
(RT-ARMS)
RT-ARMS was developed for detection of the A1762T/G1764A
double mutation. The RT-ARMS was  performed in a 50-L reac-
tion  mixture containing: 0.15 M ARMS primer (p6), 0.15 M
forward  primer (p5), 0.15 M TaqMan probe (p8), optimized
concentration of Mg2+ ions, dNTP and polymerase mix  (Takara
Premix  Ex Taq, TaKaRa Bioech, Dalian, China). The cycle con-
ditions  were: 95 ◦C for 10 min, 10 cycles of 95 ◦C for 20 s, 52 ◦C
for  40 s, 72 ◦C for 30 s, followed by: 35 cycles of 95 ◦C for 20 s,
54 ◦C for 40 s, and 72 ◦C for 30 s. The PCR was  carried on using
7500  real-time PCR (Applied Biosystems).
Results
Primer  and  probe  design
To avoid confusion of base differences among genotypes
A–E,  a total of 839 full-length HBV genome sequences were
downloaded from GenBank sequence database and analyzed
by  MEGA 4.0 (http://www.ncbi.nlm.nih.gov). According to the
ARMS technique, the reverse primer speciﬁcally designed for
detecting A1762T/G1764A double mutation, an additional mis-
match at the n−1 position next to the 3′-end base of the
ARMS  primer decreased the ampliﬁcation efﬁciency of the sin-
gle mutation and wild target sequence to a greater extent
than  that of the double mutation target sequence. For the
signal  system, TaqMan probe was  used instead of molecular
beacon (Table 1). Primers and probes were designed accord-
ing  to the primer and TaqMan probe design requirements.
After 48 experiments screening the ARMS primer, the reverse
primer  (p6 in Table 1) with G:G mismatch at the n − 1 posi-
tion  was better than others for detection of A176T/G1764A
double mutation (data not shown). The reaction conditions
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Table 2 – Ct value of ampliﬁcation of different concentrations of A1762T/G1764A double mutation template, single
mutation template and wild template by RT-ARMS.
A1762T/G1764A A1762T G1764A Wild
Copies/mL 1.00E+07 1.00E+03 1.00E+02 1.00E+07 1.00E+07 1.00E+07
Ct value 13.57 ± 0.60 28.28 ± 0.18 31.06 ± 0.17 32.33 ± 0.24 32.01 ± 0.26 33.29 ± 0.36
Table 3 – RT-ARMS for detecting weak populations with A1762T/G1764A double mutation in the mixture.
100% 10% 1% 0.10% 0.01% Wild
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1762T and G1764A single mutation and wild template.1.00E+04 1.00E+03 1.00E+07
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cycles  ﬂuctuation. When we  detected a low concentration
of non-double-mutation templates, such as 106, 105, and 104
copies/mL, the Ct value was >34 cycles or underdetermined
(data not shown).
To  conﬁrm the threshold Ct value, a large number of repeats
of  107 copies/mL single mutation template, 107 copies/mL wild
template,  103 copies/mL double mutation template, and 107
copies/mL mixed plasmid containing 103–106 copies/mL dou-
ble  mutation were tested by RT-ARMS. We obtained a threshold
Ct  value of 28 cycles, therefore conﬁrming development of a
sensitive and accurate RT-ARMS.
To evaluate the distinguishing ability of the assay, 3 × 107
copies/mL mixed population, which contained 107 copies/mL
of  each single mutation template, 107 copies/mL of wild
template and different concentrations of double mutation
template were tested. We  found 0.1% (∼3 × 104 copies/mL) of
double  mutant templates in the mixtures, and the Ct value
was  28 ± 0.24, which was  ﬁve cycles ahead of detection of 107
copies/mL wild template (Table 3), and the results matched
the  standard Ct value.
Detection  of  clinical  samples
A total of 50 clinical samples were collected from HBV-infected
patients and analyzed by the RT-ARMS and sequencing in
a  double-blind manner in two different laboratories. The
results  are summarized in Table 4. Twenty-eight samples (56%)
were A1762/G1764A dual mutation by RT-ARMS and sequenc-
ing.  Three samples were  identiﬁed with double mutations by
sequencing an additional TA clone, but the concentration was
outside  the limit of the RT-ARMS. Another three samples had
double  mutations by RT-ARMS, but could not be detected by
sequencing  due to low mutant copy numbers contained in
the  HBV population. Of all 50 patients, 40 were  diagnosed
Table 4 – Comparison of the results of ARMS and
sequencing for detecting hepatitis B virus
A1762T/G1764A mutant.
Results of ARMS Results of sequencing
Double
mutation
Single mutation
or  wild type
Double mutation (n = 31) 28 3
Single mutation or wild
type  (n = 19)
3  16
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clinically; there were  27 patients with chronic hepatitis B and
13  with severe liver disease (seven patients with cirrhosis, one
primary hepatic carcinoma, one hepatic encephalopathy, and
four  with chronic severe hepatitis). Eleven out of 13 patients
(84%)  with severe liver disease carried A1762T/G1764A dou-
ble  mutation. The genotypes of the samples were tested by
sequencing,  and 11 (22%) were genotype B and 39 (78%) were
genotype  C. Among those with A1762T/G1764A double muta-
tion,  there were 45% of genotype B and 74% of genotype C.
Discussion
Accumulated evidence shows that HBV carriers with
A1762T/G1764A double mutation in the BCP region are
signiﬁcantly associated with HCC. Patients with these muta-
tions  die at an earlier age from HCC than those without
the  mutations.6–9 Beyond that, there is ∼70% increased risk
of  HCC in individuals with these mutations and total HBV
plasma  level of >10 000 copies/mL.16 The A1762T/G1764A
double mutation is not only a predictive biomarker for HCC
development, but also a prognostic indicator of life expectancy
of  the patient with HCC.8 Thus, it is very important to detect
these  mutations.
Detection of HBV BCP mutations by using a TaqMan real-
time  PCR and LNA-blocker Simple-Probe-based real-time PCR
has been previously reported.16,19,21 Since there are more  sin-
gle  nucleotide polymorphisms (SNPs) next to A1762T and
G1764A  double mutations TaqMan real-time PCR is not a good
choice  of method to detect these mutations. Although it is
easy  to avoid this by using the LNA-clamp PCR assay, it is a
two-step  PCR assay and only available for research use.19 The
INNO  LiPA assay is simple and accurate, but the entire assay
from  DNA extraction to development of color reaction is com-
pleted  within 12 h, and the hybridization is complex. Detection
of  HBV mutations has been greatly dependent on direct DNA
sequencing,  which is considered to be the gold standard. How-
ever,  DNA sequencing only distinguishes mutations >25% in
mixed virus populations.
RT-ARMS  is an accurate and stable assay and widely used
to  detect SNPs and mutations.22–28 We  developed an RT-ARMS
to  detect A1762T/G1764A double mutation, even at concen-
trations  below the currently used thresholds. The RT-ARMS
enabled the monitoring of double mutations in the BCP region.
The  limitation of the assay is that novel polymorphisms not
yet  registered in the GenBank sequence database are not incor-
porated  within the primer design. The RT-ARMS had high
sensitivity, speciﬁcity and stability for detecting these muta-
tions,  and ∼103 copies/mL double mutation templates and
0.1%  percent double mutation template contained in 3 × 107
copies/mL mixture could be detected. Although it is not as
sensitive  as PNA-LNA-Clamp PCR (PBPPO), the RT-ARMS does
not  need nested PCR, and the assay effectively eliminates sin-
gle mutation interference, which other assays do not do. As a
result, the RT-ARMS is a functional, simple and accurate assay
that  can be used in the clinical laboratory for detecting HBV
A1762T/G1764A double mutation.
Patients have a high risk of severe liver disease
in Changzhou Jiangsu province, China, because the
A1762T/G1764 mutations and HBV genotype C are highly
1 1 4;1  8(3):261–265
prevalent in this area. It is a major concern that patients with
HBV  genotype C infection carrying these mutations have a
high  risk of HCC.6–9,13,29 Our results matched those in a recent
report.30 Among 13 patients with severe liver disease, 11 of
them  tested positive for A1762T/G1764A double mutation,
and  seven of them had these two markers. Although the
patient  sample size is small, these mutations in the BCP
region  are found in patients with serious liver disease such
as  cirrhosis and post-hepatitis B cirrhosis. These mutations
could  be an indicator of serious liver disease development.29
However, among HBeAg-positive and negative patients, the
percentage  with the double mutation was  almost the same,
which  differs from previously reported data.31 This suggests
some  divergence in different cities or provinces in China and
other  areas.
Although it is difﬁcult to design an RT-PCR to detect
A1762T/G1764A double mutation,19 we developed an RT-ARMS
that  has the potential for early and accurate detection of minor
viral  populations, before they emerge as major viral popula-
tions  that may  inﬂuence the natural history of HBV infection.
In  conclusion, the RT-ARMS represents a simple but efﬁcient
method  for the identiﬁcation of minor variants in mixed viral
populations  and may  provide a helpful tool in monitoring BCP
double  mutation.
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